CLDX — Celldex Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$39.74
+$0.50 (+1.29%)
Celldex Therapeutics Inc (CLDX) is a biotechnology company listed on NASDAQ. It is led by Anthony S. Marucci M.B.A., based in Perryville III Building, Hampton, NJ, United States, 08827, with about 198 employees. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Latest reported CLDX revenue for 2025-09-30 was $1.4M. Net income was -$67.0M. Revenue was up 95.1% from 2025-06-30 to 2025-09-30. CLDX currently screens at market cap $2.35B.
Use this CLDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CLDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CLDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Celldex Therapeutics Inc even when a live quote feed is slow.
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
CLDX Key Statistics
Market Cap
$2.35B
Volume
183,832
Previous Close
$41.22
Day Range
$40.06 – $42.12
EPS
-$2.45
Revenue
$7.02M
Net Income
$0.00
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+2.0%
Profit Margin
0.0%
Employees
198
CLDX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $7.02M | $6.88M | $2.36M | $4.65M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | -$2.45 | -$2.92 | -$2.40 | -$1.64 |
Total Assets
$792.34M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$28.36M
Operating Cash Flow
-$157.78M
Free Cash Flow
$0.00
Celldex Therapeutics Inc Company Information
- Founder, President, CEO & Director
- Anthony S. Marucci M.B.A.
- Headquarters
- Perryville III Building, Hampton, NJ, United States, 08827
- Website
- www.celldex.com
- Phone
- 908 200 7500
- IPO / Founded
- 2008-03-10
- Sector
- Healthcare
- Industry
- Biotechnology